Treatments and outcomes of adults aged ≥ 65 years admitted to acute care hospital with COVID-19
| Characteristic | No. (%) of patients* n = 927 | No. (%) of records missing n = 927 |
|---|---|---|
| COVID-19 treatment | ||
| Dexamethasone | 460 (49.6) | 0 |
| Azithromycin | 203 (21.9) | 0 |
| Remdesivir | 99 (10.7) | 0 |
| Other steroid | 56 (6.0) | 0 |
| Tocilizumab | 25 (2.7) | 0 |
| Convalescent plasma | 18 (1.9) | 0 |
| Lopinavir or ritonavir | 6 (0.6) | 0 |
| Hydroxychloroquine | 4 (0.4) | 0 |
| Participation in clinical trial | 80 (8.6) | 12 (1.3) |
| Surgery in hospital | 44 (4.7) | 4 (0.4) |
| Outcomes | ||
| In-hospital death | 262 (28.4) | 3 (0.3) |
| Length of stay, median (IQR) | 11.0 (6.0–22.0) | 13 (1.4) |
| Delirium prevalence | 497 (53.6) | 0 |
| Delirium incidence† | 201/608 (33.1) | 0 |
| ICU admission | 215 (23.4) | 8 (0.9) |
| Any complications | 432 (46.6) | 0 |
| Palliative care in hospital | 199 (21.5) | 9 (1.0) |
| Complications | ||
| Use of restraints | 189 (20.4) | 0 |
| Respiratory failure | 154 (16.6) | 0 |
| Acute respiratory distress syndrome | 101 (10.9) | 0 |
| Other infection | 68 (7.3) | 0 |
| Aspiration | 59 (6.4) | 0 |
| Hospital-acquired pneumonia | 45 (4.9) | 0 |
| In-hospital fall | 45 (4.9) | 0 |
| Stroke | 22 (2.4) | 0 |
| Pulmonary embolism | 20 (2.2) | 0 |
| Heart failure | 19 (2.0) | 0 |
| Myocardial infarction | 18 (1.9) | 0 |
| Deep vein thrombosis | 9 (1.0) | 0 |